The present invention relates to a hemifumarate form of 9-[(R)-2-[[(S)-1-(isopropoxy-carbonyl)]]] me-thoxylpropylladenine (tenofovir alafenamide) and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HTV and anti-HBV therapies).

Claims: 67